Strategic Developments in 3D Bioprinting Market: What’s New?

1
Strategic Developments in 3D Bioprinting Market
What's New?
3D bioprinting largely focuses on the fabrication
of anatomical replicas. It offers significant
accuracy in the spatial placement of
biomaterials, drugs, DNA, proteins, and cells to
better guide tissue formation and generation.
According to Inkwood Research, the global 3D
bioprinting market is expected to project a CAGR
of 16.69 during 2023-2032 and garner a revenue
of 5693.82 million by 2032.

• This blog focuses on the new strategic
  developments in the 3D bioprinting market.
• Amgen's Accelerated Drug Testing using a Human
  Tonsil
• Researchers at Amgen British Columbia are using a
  human tonsil obtained from tonsillectomies to
  produce a complex cell culture platform to mimic
  the immune system outside the body. Tonsil tissue
  encompasses a rich source of immune cells. These
  include B cells that create antibodies and helper
  T cells that nudge B cells to make targeted
  antibodies.
• Upon being provided the materials to culture the
  tonsil tissue, the cells formed 3D clusters
  spontaneously. These behave similarly to that in
  the body. The researchers plan to use these
  cultures to test medicines to better understand a
  drug's ability to elicit an immune response.
• According to Chadwick King, executive director of
  Research and site head of Amgen British Columbia,
  "In this case we are using three-dimensional
  organoid-like structures that allow us to better
  replicate human immunity. The long-term goal is
  to learn from this biology so we can better
  predict immunity using Artificial Intelligence
  (AI) and Machine Learning (ML) in the future."
  (Source)

2

• Predicting which protein-based medicines evoke an
  immune response that can neutralize the molecule
  remains a big pain point in drug development.
  Accordingly, the immune tissue platforms may
  assist in producing new antibodies for
  development.
• BioArm joins Cancer Research
• Researchers at the University of Cambridge and
  King's College London developed BioArm, a low-
  cost extrusion-based bioprinter. It can be easily
  transported, folded, and reassembled for
  printing. It can manufacture complex tumoroids
  (around 90 seconds per tumoroid) to test
  potential immunotherapy treatments. Tumoroids are
  3D cell cultures that mimic tumor tissues.
• Immunotherapy uses the immune system to identify
  and fight cancer cells. There have been increased
  efforts to mimic the tumor microenvironment with
  regard to in vitro cancer models for therapeutic
  testing. Also, modeling a tumor in vitro can help
  minimize the animal model used for treatment
  methods in cancer research.
• In this regard, 3D bioprinting is an efficient
  tool to help construct in vitro cancer models.
  However, the existing bioprinters are difficult
  to maneuver or reassemble. In comparison, BioArm
  is portable and can be assembled and disassembled
  within 15 minutes.
• Corrado Mazzaglia, Research Associate in the
  Biointerface Research Group, says, "Bioprinted
  cancer models mimic the 3D heterogeneity of real
  tumors. BioArm has the potential to screen a wide
  range of tumor therapies and could play a crucial
  role in the future development of cancer drug
  testing approaches." (Source)
• CollPlant and Stratsys merge Technologies for
  Industrial-Scale Bioprinting of Organs and
  Tissues
• On 4th April 2023, Stratasys and CollPlant
  announced a joint development commercialization
  agreement to develop a solution to bio-fabricate
  human organs and tissues. This will be done using
  CollPlant's collagen-based bioinks and Stratasys'
  P3 technology-based bioprinter. It will further
  enable the production of CollPlant's
  state-of-the-art breast implants designed to
  regenerate an individual's natural breast tissue
  without evoking an immune response. This is
  evaluated to facilitate a revolutionary
  alternative for reconstructive and aesthetic
  procedures.
• Says Yehiel Tal, CEO of CollPlant, "We believe
  that our rhCollagen-based regenerative implant
  has the potential to overcome the challenges of
  existing breast procedures that use silicone
  implants or autologous fat tissue transfer."
  (Source)
• Easy Gulping DEGLUMED's 3D Printed Personalized
  Medicine to Dysphagia Rescue
• Dysphagia is a swallowing disorder. It affects 1
  in 25 people in the United States. Dysphagia
  patients need more time and effort to move food
  from the mouth to the stomach. Also, it affects
  patients with neurodegenerative pathologies. For
  instance, over 50 of acute stroke patients in
  Europe are affected by post-stroke dysphagia
  (PSD).
• DEGLUMED is a Spanish project funded by the
  Valencian Institute of Business Competitiveness
  (IVACE). The participants include Centrum
  Pharmaceutical Specialties, IT3D GROUP,
  NutriSpain, and AIMPLAS (Plastics Technology
  Centre). The project aims to provide solutions
  for people with swallowing problems.
• The project integrates several technologies and
  methods to design drugs. These include hot melt
  extrusion, which facilitates complex formulations
  that can be used to obtain films. These films

3

• further disintegrate in the mouth. Additionally,
  a filament would be acquired to be used for Fused
  Deposition Modeling (FDM) 3D printing.
• 3D printing is evaluated to save energy and
  enable the bioavailability and reproducibility of
  the drug. Also, it offers advantages like the
  production versatility of short series at
  affordable costs, savings in materials,
  personalization, the printing of complex
  structures integrating different materials, etc.
• Toward Four-Dimensional (4D) Bioprinting?
• In 4D bioprinting, the fourth dimension, 'time,'
  is incorporated with 3D bioprinting. The printed
  bioconstructs can change their functionalities or
  shapes either through external or internal
  stimuli. It is estimated to be a promising
  direction in the fabrication of living tissues in
  a shorter duration of in vitro culture. This does
  not require extensive casting in molds that
  prevent the integration of larger tissues with
  vascular networks or their fabrication.
• One of our major findings with regard to the
  global 3D bioprinting market is the emergence of
  4D bioprinting as a substitute for 3D
  bioprinting. It is assessed to be a disruptive
  innovation in tissue engineering since it
  facilitates the construction of functional
  complex structures with stimuli- responsive
  materials.
• FAQs
• Which region projects immense growth potential in
  the global 3D bioprinting market?
• A Asia-Pacific projects immense growth potential
  in the global 3D bioprinting market.
• What are the main growth restraints of the global
  3D bioprinting market?
• A Operational challenges and the lack of skilled
  professionals are the global 3D bioprinting
  market.